engleski

Immune response and clinical findings in uveitis, optic neuritis and multiple sclerosis during Peptid-M (Lupex) therapy

Peptid-M is a small molecular mass neuropeptie (PENK, 100-104 aa), present in low quantity in different tissue including thymus. We analysed the results of peptid-M therapy in 21 patients with anterior uveitis, Behçet's disease, intermediate uveitis, optic neuritis and elapsing-remitting multiple sclerosis. Peptid-M (Lupex, Biofactor, Germany) was administered s.c. 0.25 mg/kg 5 times weekly for 4 weeks, then gradually reduced to 0.25 mg/kg weekly devided in 2 doses for >6 months. After peptide-M administration we observed marked rise in serum IFN levels, modulation of phagocite functions, NK activity, serum IL-4 and lowering of CD3+CD16+56 + cells. Clinical amelioration was noticed in all patients with uveitis and optic neuritis and in 10/12 MS patients. Improvements of VEP, colour vision, visual field abnormalities, EDSS and MRI findings were observed in most of the patients.

peptid-M; peptide therapy; anterior uveitis; Behçet's disease; intermediate uveitis; optic neuritis; multiple sclerosis; immunomodulation

Ocular Immunology and Inflammation (0927-3948) 6 (1998) (Suppl.)